Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
COYA vs FENC: Clinical Biotech Potential Meets Commercial Pharma Stability

COYA vs FENC: Clinical Biotech Potential Meets Commercial Pharma Stability

Key Takeaways

  • COYA is a clinical-stage biotech focused on regulatory T cell (Treg) therapies, while FENC is a commercial-stage specialty pharma with a marketed product.
  • FENC reported record third-quarter net product sales of $19.4 million (up 56% year over year) and turned GAAP net income positive; COYA posted roughly $234,000 in collaboration revenue and a widening net loss.
  • Relative performance has diverged sharply in recent weeks: FENC trades near the upper end of its 52-week range, while COYA has pulled back meaningfully from prior highs.
  • Tickeron AI Verdict: FENC is the ticker of choice, favored for its trend consistency, profitability, and positive operating cash flow.
  • Both names carry distinct risk profiles: COYA faces binary clinical-trial risk, while FENC faces niche-market penetration and product-maturity risk.
  • For more detail, explore COYA Major News and COYA Today's Price Move, plus FENC Major News and FENC Today's Price Move.
  • To see how AI trading systems are positioning across the market, explore Trending AI Robots.

Setting the Stage

This comparison looks at two healthcare companies at very different points in their development. COYA (Coya Therapeutics) is advancing immune-modulating therapies for neurodegenerative diseases as a clinical-stage biotech. FENC (Fennec Pharmaceuticals) markets PEDMARK as a commercial-stage specialty pharma. The contrast highlights the trade-offs between speculative, catalyst-driven exposure and a revenue-generating, cash-flow-positive story. I reviewed the latest data points to clarify which profile aligns better with current market conditions.

COYA Overview and Recent Performance

Coya Therapeutics is developing biologics to enhance regulatory T cells (Tregs) that help control inflammation. Its lead candidate, COYA 302, is in the Phase 2/3 ALSTARS trial for amyotrophic lateral sclerosis (ALS). The company recently completed enrollment of 120 participants and moved into a blinded extension phase, which supports the program's timeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Despite the progress, shares have faced pressure. Collaboration revenue came in at roughly $234,000, down from the prior year, with a wider net loss. The stock has declined over the past month and sits lower in its 52-week range. Analyst consensus remains a Strong Buy with targets above current levels, but trading reflects reliance on future data rather than current cash flow.

FENC Overview and Recent Performance

Fennec Pharmaceuticals markets PEDMARK, the only FDA-approved therapy to reduce cisplatin-induced hearing loss in certain pediatric cancer patients. The company now generates recurring revenue and has reached profitability. In the latest quarter, FENC posted net product sales of $19.4 million, up 56% year over year, with record non-GAAP adjusted EBITDA of about $5.8 million and GAAP net income of $4.6 million. Project Ignite sales expansion has supported growth and record patient numbers. Operating cash flow reached roughly $6.7 million, boosting cash to $48.7 million with no debt. The stock has moved toward the upper end of its 52-week range, aided by raised price targets and expectations for continued momentum.

Head-to-Head Comparison

The companies represent opposite ends of the biopharma lifecycle. COYA carries high-risk, high-upside potential linked to one pivotal trial and a cash runway into 2027, with valuation driven by clinical events. FENC offers a proven product, expanding adoption, and a debt-free balance sheet for steadier fundamentals. Growth drivers differ sharply as well. COYA depends on topline ALSTARS data and regulatory steps that can trigger sharp swings. FENC focuses on incremental factors like formulary wins and potential label expansions. Momentum favors FENC with consistent trends and improving profitability, while COYA shows higher volatility and a recent pullback.

Tickeron AI Verdict

Based on trend consistency, stability, catalysts, and positioning, Tickeron's AI currently favors FENC. Accelerating revenue, positive GAAP earnings, record operating cash flow, and a debt-free balance sheet create a more stable foundation than COYA's pre-revenue profile. While COYA holds upside from its trial, the binary nature aligns less with steady-trend characteristics that models tend to reward now. The preference is probabilistic and reflects relative positioning.

Using Tickeron AI Tools for Deeper Analysis

In my own research process, I often turn to Tickeron’s suite of AI tools to cross-check positioning and signals across names like these. The platform’s bots and pattern engines help surface relative strength and trend data that complement traditional fundamentals. For traders looking to automate aspects of this analysis, the AI Trading Bots section offers curated systems with historical statistics and current market exposure that can be reviewed side by side.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FENC, COYA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


FENC's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for FENC turned positive on November 09, 2026. Looking at past instances where FENC's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on FENC as a result. In 90 of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

FENC moved above its 50-day moving average on November 12, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FENC crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +16.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 203 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

FENC broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for FENC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.105) is normal, around the industry mean (3.592). FENC has a moderately low P/E Ratio (-81.750) as compared to the industry average of (-1.190). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic products based on cell adhesion

Industry Biotechnology

Industry
Biotechnology
Address
68 TW Alexander Drive
Phone
+1 919 636-4530
Employees
35
Web
https://www.fennecpharma.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.